Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Imogam Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
Historical expansion was propelled by several factors, including significant fatalities from rabies, restricted early availability of vaccines, reliance on passive immunity products, widespread public health vaccination programs, and hospital-based emergency care.
The anticipated expansion during the forecast period is fueled by an uptick in animal bite incidents, the spread of rabies awareness initiatives, an increase in emergency healthcare infrastructure, improved access to immunoglobulins, and enhanced government investment in controlling zoonotic diseases.
Significant developments expected in the forecast period encompass sustained demand for rabies post-exposure prophylaxis, broader application of passive immunization, an increased focus on preventing zoonotic diseases, growth in the administration of emergency immunoglobulins, and strengthened public health preparedness.
Get A Free Sample Report With In-Depth Market Insights:
Imogam Market Growth Factors Behind Sustained Expansion
The imogam market is anticipated to grow in response to the rising incidence of animal bites. Animal bites are events where individuals sustain injuries from animals, frequently requiring medical attention. This increase in animal bite cases is attributed to factors such as an expanding pet population, inadequate animal control, and more human-animal interactions. Imogam is administered for immediate post-exposure prophylaxis to victims of animal bites, providing passive immunity against rabies until the rabies vaccine takes effect. For instance, in September 2024, Dogster, a US-based bimonthly magazine and website, published an article indicating 6,000 dog bite incidents occurred in 2023. Additionally, dog bite fatalities rose fivefold, from 5 in 2022 to 15 in 2023. Therefore, the growing number of animal bites is a significant catalyst for the imogam market’s expansion.
Imogam Market Segment Analysis Spotlighting Growth Areas
The imogam market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients, High-Risk Groups
2) By Application: Post-Exposure Prophylaxis, Pre-Exposure Prophylaxis
3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Pharmacies
Imogam Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the imogam market are Sanofi SA
View The Full Imogam Market Report:
Imogam Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the imogam market in 2025. The regions covered in the imogam market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model








